February 14, 2018 / 9:43 AM / 2 months ago

BRIEF-Glaxosmithkline Submits Landmark Impact Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta​

Feb 14 (Reuters) - Glaxosmithkline Plc:

* ‍GSK SUBMITS LANDMARK IMPACT DATA TO EUROPEAN MEDICINES AGENCY TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below